Tofacitinib citrate CAS NO.540737-29-9

1,we produce and sell good chemicals around the world.
2,our success rate is about 95%. this means, if customer order is accepted, the probability that the customer will obtain the ordered substances, is 95%.
3,our staff consists of highly qualified individuals with bsc, msc and ph.d degrees in chemistry, as well as excellent carbohydrates,nucleosides, small molecules and rare chemicals.
4,imaginechem's chemists are skilled at performing complex, multi-step syntheses and solving difficult chemistry-related problems. because of our better, concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery.
5,all chemicals are typically >97% for building blocks, the structure and purity is confirmed by nmr and lc-ms. intermediates and final products are analyzed by gc, hplc, ir, nmr, ms, elemental analysis, atom-absorpting analysis and crystallographical methods.
165,Customers-oriented strategy, exclusive supply chain management, professional R&D team, experienced production workers, energetic sales team enable us to offer best service andgood-value products to all of our customers and gradually reach our final goals: becoming global leading supplier for portable products and solutions.

Product Name:    Tofacitinib citrate
Synonyms:    1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);Xeljanz;CP-690550 (Tofacitinib citrate);(3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate;CP 690500-10;CP 690550-10;1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-, citrate
CAS:    540737-29-9
form     powder
color     white to beige
Description    Tofacitinib citrate, also known as CP-690550 citrate, is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.